New kits reduce use of plastics by up to 62% and cardboard by up to 58% compared to QIAGEN standard kits // Two additions to growing QIAwave portfolio: QIAwave RNeasy Plus Mini Kit and QIAwave DNA ...

QIAGEN has historically allocated global production capacity to manufacture RNA nucleic extraction reagents to supply about 1.5 million patient tests on a monthly basis.

QIAGEN N.V. QGEN recently added two new nucleic acid extraction kits, extending its eco-friendly QIAwave product line. The two new kits are the QIAwave RNeasy Plus Mini Kit and the QIAwave DNA/RNA ...

Qiagen, an international company that makes a critical part of diagnostic tests for the novel coronavirus, announced this week that it is ramping up production of their RNA extraction kits in the ...

Venlo, the Netherlands, Nov. 15, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its sample technologies portfolio with the ...

Goal to reach global capacity for RNA nucleic extraction ... June 2020 and to reach capacity for 20 million monthly patient tests by end of 2020 Welcomes FDA and CDC expansion of QIAGEN kits ...

Venlo, the Netherlands, Sept. 25, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the extension of its e Tuesday, 02 January 2024 12:17 GMT عربي ...

“QIAGEN teams are working 24/7 to address the unprecedented demand for reagents that has emerged to enable testing for COVID-19 in terms of RNA extraction, as well as for production of tests for use ...

* QIAGEN NV - RAMPING UP GLOBAL PRODUCTION CAPACITY FOR RNA EXTRACTION KITS FOR USE IN DETECTION OF SARS-COV-2 CORONAVIRUS * QIAGEN - RAMPING UP PRODUCTION CAPACITY FOR REAGENTS TO SUPPORT A LEVEL ...